[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603914":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":33,"centralContacts":37,"locations":45,"responsibleParty":87,"collaborators":33,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":33,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":33,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":48,"whyStopped":33,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"MBX Biosciences","INDUSTRY",[8,14,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"MBX 4291 (Part A)","EXPERIMENTAL","Participants will be administered single ascending doses of MBX 4291, or matching placebo.",[13],"Drug: MBX 4291",{"label":15,"type":10,"description":16,"interventionNames":17},"MBX 4291 (Part B)","Participants will be administered multiple ascending doses of MBX 4291, or matching placebo.",[13],{"label":19,"type":10,"description":16,"interventionNames":20},"MBX 4291 (Part C)",[13],{"label":22,"type":23,"description":24,"interventionNames":25},"Placebo","PLACEBO_COMPARATOR","Participants will be administered single or multiple ascending doses of placebo.",[26],"Drug: Placebo",[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","MBX 4291","MBX 4291 will be administered subcutaneously (SC)",[9,15,19],null,{"type":29,"name":22,"description":35,"armGroupLabels":36,"otherNames":33},"Placebo: Placebo will be administered subcutaneously (SC)",[22],[38,43],{"name":39,"role":40,"phone":41,"phoneExt":33,"email":42},"Elisa Fabbrini, MD, PhD","CONTACT","844-877-4473","MBX4291.Clinicaltrials@mbxbio.com",{"name":44,"role":40,"phone":41,"phoneExt":33,"email":42},"Stewart Hallett",[46,60,69,78],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":33},"MBX Biosciences Investigational Site","RECRUITING","Doral","Florida","33172","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-80.35533,25.81954,{"lat":58,"lon":57},{"facility":47,"status":48,"city":61,"state":62,"zip":63,"country":52,"countryCode":53,"cosmosGeoPoint":64,"geoPoint":68,"contacts":33},"Lexington","Kentucky","40509",{"type":55,"coordinates":65},[66,67],-84.47772,37.98869,{"lat":67,"lon":66},{"facility":47,"status":48,"city":70,"state":71,"zip":72,"country":52,"countryCode":53,"cosmosGeoPoint":73,"geoPoint":77,"contacts":33},"Kansas City","Missouri","64114",{"type":55,"coordinates":74},[75,76],-94.57857,39.09973,{"lat":76,"lon":75},{"facility":47,"status":48,"city":79,"state":80,"zip":81,"country":52,"countryCode":53,"cosmosGeoPoint":82,"geoPoint":86,"contacts":33},"Knoxville","Tennessee","37920",{"type":55,"coordinates":83},[84,85],-83.92074,35.96064,{"lat":85,"lon":84},{"type":88,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100603914","phase-1-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-mbx-4291-in-adult-participants-with-obesity-100603914",false,"NCT07142707","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity","A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity","Inclusion Criteria:\n\n* Age of \\>18 to ≤65 years at the time of signing the informed consent.\n* Has a BMI of ≥30 to \\\u003C50 kg\u002Fm2 at screening and baseline.\n* Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.\n\nExclusion Criteria:\n\n* History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.\n* History of currently active pancreatitis, type I and type II diabetes.\n* Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.\n* A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.","ALL","18 Years","65 Years",{"count":100,"type":101},124,"ESTIMATED","INTERVENTIONAL",[104],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.",[107],"Obesity",[109,110,111,112],"Body Weight","Body Mass Index","Overweight","Nutrition Disorders","2026-06-08",{"date":115,"type":116},"2026-06-09","ACTUAL",{"date":118,"type":116},"2025-09-03",{"date":120,"type":101},"2026-10-30",{"name":5,"class":6},4]